In the coming 10 years TBVI hopes to raise 200 million euros from governments, foundations and private industry for the discovery and early clinical development of new vaccines. Development of new vaccines is crucial because the only existing vaccine, BCG, is not very effective in young adults, the group of people mostly affected by the disease.
“New vaccines are essential to achieve the international aim of a TB-free world in 2050. We need several types, not only for initial protection against TB, but also to boost adolescent immunity and prevent disease in latently infected individuals,” explains Jelle Thole, director of TBVI. “To enable development of these vaccines, more investment is needed.”
TBVI financially and practically supports and facilitates a growing international network of over thirty universities, institutes and industries involved in research and development of new TB vaccines. The organization evolved from TBVAC, a European Union (EU) funded project to identify good candidates for new TB vaccines. TBVAC has yielded five new TB vaccine candidates, fifteen candidate biomarkers and three candidate adjuvant molecules. These hopeful candidates are now in preclinical development or even clinical phase.
TBVI is extremely pleased with the encouraging new signs of progress on TB. “Because of this funding, we can continue to change new discoveries into real vaccines,” says Joris Vandeputte, senior vice president Fundraising & Advocacy at TBVI. “These vaccines are urgently needed, as the resurrection of TB is a ticking time bomb. Many people believe it is a disease of the past, but in fact it is endangering our future, taking almost 1.8 million lives a year.”
The global burden of TB is slowly falling, but still two billion people, about one third of the world’s population, are estimated to be infected with the mycobacteria that cause TB. Most of them develop a latent infection, with about a 10 percent risk of developing the infectious disease later in life. People with HIV are 20 times more likely to develop the symptoms once they are infected. Efficient drugs to treat TB are available, but involve a long and burdensome treatment period of up to a year. Additionally, worldwide prevalence of various forms of drug-resistant TB poses an increasing problem and enormous challenges to effective treatment.
With new infections occurring at a rate of one per second, millions of people develop TB symptoms every year. In 2007, there were 9.27 million new cases. 500,000 of those were multi-drug resistant and 50,000 of those were extensively drug resistant (source: World Health Organization).
The quest for the oldest ice on Earth
14.11.2016 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung
Empa Innovation Award for new flame retardant
09.11.2016 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy